From: Disease trajectories in interstitial lung diseases – data from the EXCITING-ILD registry
N = 530 | Survival time (years) | Survival time vs. IPF | Time to progression (months) | Time to progression vs. IPF | |||
---|---|---|---|---|---|---|---|
Median (range) | HR [95% CI] | p value (Wald test) | Median (range) | HR [95% CI] | p value (Wald test) | ||
ILD Subtype | IPF (n = 152) | 5.8 (0.6–14.5) | 18.9 (1.1–47.54) | ||||
iNSIP (n = 42) | 9.2 (0.4–18.3) | 0.83 [0.47, 1.48] | 0.535 | 14.6 (0.9–32.69) | 1.08 [0.7, 1.67] | 0.728 | |
COP (n = 25) | n.e. (0.7–3.2) | 0.53 [0.21, 1.31] | 0.171 | 40.1 (1.7–42.02) | 0.5 [0.27, 0.9] | 0.021 | |
uILD (n = 34) | 5.6 (0.2–5.6) | 0.97 [0.54, 1.75] | 0.923 | 21.6 (0.1–44.94) | 0.8 [0.5, 1.28] | 0.351 | |
Sarcoidosis (n = 160) | n.e. (1.2–34.4) | 0.33 [0.18, 0.63] | < 0.001 | n.e. (0.2–46.59) | 0.31 [0.22, 0.43] | < 0.001 | |
HP (n = 58) | 16.0 (1.6–22.6) | 0.3 [0.17, 0.53] | < 0.001 | 32.4 (4.8–40.28) | 0.6 [0.4, 0.89] | 0.011 | |
CTD-ILD (n = 43) | 15.5 (0.6–15.5) | 0.33 [0.18, 0.6 | < 0.001 | 22.2 (3.0–36.47) | 0.78 [0.5, 1.21] | 0.262 | |
DI-ILD (n = 16) | 6.0 (0.2–6.0) | 1.41 [0.68, 2.93] | 0.358 | 23.7 (0.5–43.43) | 0.75 [0.41, 1.4] | 0.372 | |
N = 601 | Survival time (years) | ||||||
Median (range) | HR [95% CI] | p value (Wald test) | |||||
ILD-GAP Index | II vs. I | 4.95 [3.02, 8.11] | < 0.001 | ||||
III vs. I | 9.06 [5.58, 14.71] | < 0.001 | |||||
No PFT vs. I | 4.34 [2.13, 8.83] | < 0.001 | |||||
AE-ILD | AE-ILD (n = 124) | 7.3 (0.1–34.4) | 0.39 [0.29, 0.53] | < 0.001 | |||
No AE-ILD (n = 477) | 19.6 (0.3–19.6) | ||||||
LTOT | LTOT (n = 164) | 6.1 (0.1–34.4) | 0.26 [0.19, 0.36] | < 0.001 | |||
No LTOT (n = 437) | n.e. (0.2–19.1) |